Guro Lindviksmoen Astrup1,2, Kristin Hofsø3,4, Kristin Bjordal2,5, Marianne Grønlie Guren6, Ingvild Vistad7, Bruce Cooper8, Christine Miaskowski8, Tone Rustøen3,9. 1. a Department of Oncology, Division of Cancer Medicine , Oslo University Hospital , Oslo , Norway. 2. b Institute of Clinical Medicine, Faculty of Medicine, University of Oslo , Oslo , Norway. 3. c Department of Research and Development, Division of Emergencies and Critical Care , Oslo University Hospital , Oslo , Norway. 4. d Lovisenberg Diaconal University College , Oslo , Norway. 5. e Research Support Services, Oslo University Hospital , Oslo , Norway. 6. f Department of Oncology and K.G. Jebsen Colorectal Cancer Research Centre, Division of Cancer Medicine , Oslo University Hospital , Oslo , Norway. 7. g Department of Obstetrics and Gynecology , Division of Surgery, Sørlandet Hospital HF , Kristiansand , Norway. 8. h School of Nursing , University of California , San Francisco , CA , USA. 9. i Institute of Health and Society, Faculty of Medicine, University of Oslo , Oslo , Norway.
Abstract
CONTEXT: Reviews of the literature on symptoms in oncology patients undergoing curative treatment, as well as patients receiving palliative care, suggest that they experience multiple, co-occurring symptoms and side effects. OBJECTIVES: The purposes of this study were to determine if subgroups of oncology patients could be identified based on symptom occurrence rates and if these subgroups differed on a number of demographic and clinical characteristics, as well as on quality of life (QoL) outcomes. METHODS: Latent class analysis (LCA) was used to identify subgroups (i.e. latent classes) of patients with distinct symptom experiences based on the occurrence rates for the 13 most common symptoms from the Memorial Symptom Assessment Scale. RESULTS: In total, 534 patients with breast, head and neck, colorectal, or ovarian cancer participated. Four latent classes of patients were identified based on probability of symptom occurrence: all low class [i.e. low probability for all symptoms (n = 152)], all high class (n = 149), high psychological class (n = 121), and low psychological class (n = 112). Patients in the all high class were significantly younger compared with patients in the all low class. Furthermore, compared to the other three classes, patients in the all high class had lower functional status and higher comorbidity scores, and reported poorer QoL scores. Patients in the high and low psychological classes had a moderate probability of reporting physical symptoms. Patients in the low psychological class reported a higher number of symptoms, a lower functional status, and poorer physical and total QoL scores. CONCLUSION: Distinct subgroups of oncology patients can be identified based on symptom occurrence rates. Patient characteristics that are associated with these subgroups can be used to identify patients who are at greater risk for multiple co-occurring symptoms and diminished QoL, so that these patients can be offered appropriate symptom management interventions.
CONTEXT: Reviews of the literature on symptoms in oncology patients undergoing curative treatment, as well as patients receiving palliative care, suggest that they experience multiple, co-occurring symptoms and side effects. OBJECTIVES: The purposes of this study were to determine if subgroups of oncology patients could be identified based on symptom occurrence rates and if these subgroups differed on a number of demographic and clinical characteristics, as well as on quality of life (QoL) outcomes. METHODS: Latent class analysis (LCA) was used to identify subgroups (i.e. latent classes) of patients with distinct symptom experiences based on the occurrence rates for the 13 most common symptoms from the Memorial Symptom Assessment Scale. RESULTS: In total, 534 patients with breast, head and neck, colorectal, or ovarian cancer participated. Four latent classes of patients were identified based on probability of symptom occurrence: all low class [i.e. low probability for all symptoms (n = 152)], all high class (n = 149), high psychological class (n = 121), and low psychological class (n = 112). Patients in the all high class were significantly younger compared with patients in the all low class. Furthermore, compared to the other three classes, patients in the all high class had lower functional status and higher comorbidity scores, and reported poorer QoL scores. Patients in the high and low psychological classes had a moderate probability of reporting physical symptoms. Patients in the low psychological class reported a higher number of symptoms, a lower functional status, and poorer physical and total QoL scores. CONCLUSION: Distinct subgroups of oncology patients can be identified based on symptom occurrence rates. Patient characteristics that are associated with these subgroups can be used to identify patients who are at greater risk for multiple co-occurring symptoms and diminished QoL, so that these patients can be offered appropriate symptom management interventions.
Authors: Elizabeth M Jaffee; Chi Van Dang; David B Agus; Brian M Alexander; Kenneth C Anderson; Alan Ashworth; Anna D Barker; Roshan Bastani; Sangeeta Bhatia; Jeffrey A Bluestone; Otis Brawley; Atul J Butte; Daniel G Coit; Nancy E Davidson; Mark Davis; Ronald A DePinho; Robert B Diasio; Giulio Draetta; A Lindsay Frazier; Andrew Futreal; Sam S Gambhir; Patricia A Ganz; Levi Garraway; Stanton Gerson; Sumit Gupta; James Heath; Ruth I Hoffman; Cliff Hudis; Chanita Hughes-Halbert; Ramy Ibrahim; Hossein Jadvar; Brian Kavanagh; Rick Kittles; Quynh-Thu Le; Scott M Lippman; David Mankoff; Elaine R Mardis; Deborah K Mayer; Kelly McMasters; Neal J Meropol; Beverly Mitchell; Peter Naredi; Dean Ornish; Timothy M Pawlik; Jeffrey Peppercorn; Martin G Pomper; Derek Raghavan; Christine Ritchie; Sally W Schwarz; Richard Sullivan; Richard Wahl; Jedd D Wolchok; Sandra L Wong; Alfred Yung Journal: Lancet Oncol Date: 2017-10-31 Impact factor: 41.316
Authors: Komal P Murali; Gary Yu; John D Merriman; Allison Vorderstrasse; Amy S Kelley; Abraham A Brody Journal: Nurs Res Date: 2021 Nov-Dec 01 Impact factor: 2.381
Authors: Asha Mathew; Amit Jiwan Tirkey; Hongjin Li; Alana Steffen; Mark B Lockwood; Crystal L Patil; Ardith Z Doorenbos Journal: Semin Oncol Nurs Date: 2021-09-03 Impact factor: 3.527
Authors: Nikoloas Papachristou; Payam Barnaghi; Bruce A Cooper; Xiao Hu; Roma Maguire; Kathi Apostolidis; Jo Armes; Yvette P Conley; Marilyn Hammer; Stylianos Katsaragakis; Kord M Kober; Jon D Levine; Lisa McCann; Elisabeth Patiraki; Steven M Paul; Emma Ream; Fay Wright; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2017-08-30 Impact factor: 3.612
Authors: Natalie Moryl; Vinnidhy Dave; Paul Glare; Ali Bokhari; Vivek T Malhotra; Amitabh Gulati; Joseph Hung; Vinay Puttanniah; Yvona Griffo; Roma Tickoo; Alison Wiesenthal; Susan D Horn; Charles E Inturrisi Journal: J Pain Date: 2017-11-14 Impact factor: 5.820
Authors: Danielle B Tometich; Brent J Small; Judith E Carroll; Wanting Zhai; George Luta; Xingtao Zhou; Lindsay C Kobayashi; Tim Ahles; Andrew J Saykin; Jonathan D Clapp; Heather S L Jim; Paul B Jacobsen; Arti Hurria; Deena Graham; Brenna C McDonald; Neelima Denduluri; Martine Extermann; Claudine Isaacs; Asma Dilawari; James Root; Christine Rini; Jeanne S Mandelblatt Journal: J Pain Symptom Manage Date: 2018-11-23 Impact factor: 3.612
Authors: Jorunn Drageset; Reidun Karin Sandvik; Leslie Sofia Pareja Eide; Gunhild Austrheim; Mary Fox; Elisabeth Grov Beisland Journal: Health Qual Life Outcomes Date: 2021-03-20 Impact factor: 3.186
Authors: Yufen Lin; Donald E Bailey; Sharron L Docherty; Laura S Porter; Bruce A Cooper; Steven M Paul; Kord M Kober; Marilyn J Hammer; Fay Wright; Laura B Dunn; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Support Care Cancer Date: 2021-01-16 Impact factor: 3.359
Authors: Tara L Kaufmann; Kelly D Getz; Jesse Y Hsu; Antonia V Bennett; Samuel U Takvorian; Arif H Kamal; Angela DeMichele Journal: JCO Oncol Pract Date: 2021-03-24